Editing Basiliximab (section)

== Medical uses ==
Basiliximab is [[indicated]] for the prophylaxis of acute organ rejection in de-novo allogeneic renal transplantation.<ref name="Simulect EPAR" /> It is to be used concomitantly with ciclosporin for microemulsion- and corticosteroid-based immunosuppression, in people with panel reactive antibodies less than 80%, or in a triple maintenance immunosuppressive regimen containing ciclosporin for microemulsion, corticosteroids and either azathioprine or mycophenolate mofetil.<ref name="Simulect EPAR" />

Basiliximab is an [[immunosuppressant]] agent used to prevent immediate [[transplant rejection]] in people who are receiving kidney transplants, in combination with other agents.<ref name=Medline>MedlinePlus. Last Revised - 15 June 2012 [https://www.nlm.nih.gov/medlineplus/druginfo/meds/a612013.html Basiliximab Injection] {{Webarchive|url=https://web.archive.org/web/20160705111853/https://www.nlm.nih.gov/medlineplus/druginfo/meds/a612013.html |date=5 July 2016 }}</ref> It has been reported that some cases of [[lichen planus]] have been successfully treated with basiliximab as an alternative therapy to [[cyclosporin]]. No short-term side effects have been reported.<ref>{{cite book | vauthors = Katsambas AD, Lotti TM | title = European handbook of dermatological treatments | edition = 2nd | date = 2003 | page = 291 | publisher = Springer | isbn = 3-540-00878-0 }}</ref>